ArticleAIDS care2026
Comorbidities and treatment regimens of HIV-associated lipodystrophy disease among a cohort of persons with HIV in Washington, DC.
Article in AIDS care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
HIV-associated lipodystrophy (HAL) continues to occur in persons with HIV (PWH) despite use of antiretroviral therapies (ART). The purpose of this study was to compare characteristics of PWH with and without HAL, determine associations between HAL diagnosis and medical comorbidities, describe correlates of HAL treatment and explore use of pre-HAL ART regimens among PWH in a large cohort. Using data from the DC Cohort longitudinal study of PWH in Washington, DC, we identified HAL diagnoses from 2011 to 2024 using ICD-codes and prescription medications from electronic health records. We assessed demographics, HIV measures and comorbidities of PWH with HAL and trends in ART use prior to HAL diagnosis. Among 325 cases of HAL (2.5%), most were male (75%) and non-Hispanic Black (61%). PWH with HAL were more likely to have coronary heart disease, asthma, cancer, diabetes, chronic kidney disease and mental health disorders compared to PWH without HAL. HAL prevalence decreased over time while INSTI - and NNRTI-based regimens increased. Our findings indicate gender, socioeconomic and comorbidity differences among PWH with HAL. Clinician awareness of increased odds for comorbid conditions among PWH with HAL is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.